Table 2

Association between GZMB genotype and clinical outcome

ParameterTest variablesUnivariate analysisMultivariate analysis
HR (95% CI)P valueHR (95% CI)P value
PFS
GZMB c.128T>CCC+CT vs TT1.39 (1.07 to 1.80)0.013*1.38 (1.02 to 1.87)0.036*
 WHO0 vs ≥10.66 (0.46 to 0.95)0.027*0.61 (0.42 to 0.89)0.01*
 SexMale vs female1.38 (1.06 to 1.80)0.018*1.29 (0.95 to 1.76)0.103
OS
GZMB c.128T>CCC+CT vs TT1.19 (0.91 to 1.57)0.212
 WHO0 vs ≥10.52 (0.35 to 0.77)0.001*
 SexMale vs female1.40 (1.05 to 1.86)0.023*
Parameter Test variablesUnivariate analysisMultivariate analysis
OR (95% CI)P valueOR (95% CI)P value
BOR
GZMB c.128T>CCC +CT vs TT1.63 (1.04 to 2.57)0.033*1.60 (1.01 to 2.52)0.044*
 Primary tumorOther vs adeno0.63 (0.40 to 0.98)0.041*0.63 (0.41 to 0.99)0.045*
  • Univariate and multivariate analysis of the association of germline variation of GZMB and PFS, OS, or BOR. Patient factors associated with OS/PFS (p value<0.1) were included in the multivariate analysis. Significance is marked by *.

  • BOR, best overall response; OS, overall survival; PFS, progression-free survival; WHO, WHO performance status.